Mind Medicine (mindmed) INC Form 4 insider transactions
Mind Medicine (MindMed) Inc.'s Chief Medical Officer, Daniel Karlin, sold 7,848 common shares at a weighted average price of $6.80 to satisfy tax withholding obligations related to vested restricted stock units.
Mind Medicine (MindMed) Inc. CEO Robert Barrow sold 26,491 common shares on June 25, 2025, at a weighted average price of $6.80 per share, primarily to cover tax obligations related to vested restricted stock units.
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., sold 11,491 common shares on June 25, 2025, to satisfy tax withholding obligations related to vested restricted stock units.
Mind Medicine (MindMed) Inc. Director Andreas Krebs was granted 75,187 stock options with an exercise price of $7.3, vesting monthly over a year or earlier upon the company's annual meeting.
Mind Medicine (MindMed) Inc. Director Carol A. Vallone was granted 75,187 stock options with an exercise price of $7.3 per share, aligning her interests with shareholder value.
Mind Medicine (MindMed) Inc. director Suzanne Louise Bruhn was granted 75,187 stock options with an exercise price of $7.3, as disclosed in a recent SEC Form 4 filing.
Mind Medicine (MindMed) Inc. Director Roger Crystal was granted 75,187 stock options with an exercise price of $7.30, vesting monthly over a year or sooner under certain conditions.
Mind Medicine (MindMed) Inc. Director David W. Gryska was granted 75,187 stock options with an exercise price of $7.3 per share, vesting monthly over a year or earlier under specific conditions.
Mind Medicine (MindMed) Inc.'s Chief Financial Officer, Brandi Roberts, was granted 500,000 stock options with an exercise price of $7.26, aligning her incentives with long-term shareholder value.
MindMed's CEO, Robert Barrow, sold 21,208 common shares on March 25, 2025, to cover withholding tax obligations related to vested restricted stock units.
Daniel Karlin, Chief Medical Officer of Mind Medicine (MindMed) Inc., sold 6,836 common shares on March 25, 2025, to cover withholding tax obligations related to vested restricted stock units.
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., sold 6,576 common shares on March 25, 2025, to cover withholding tax obligations related to vested restricted stock units.
Carrie Liao, Chief Accounting Officer of Mind Medicine (MindMed) Inc., reports the sale of 2,347 common shares to cover withholding tax obligations related to vested restricted stock units.
Form 4: Mind Medicine (MindMed) Inc.: Chief Commercial Officer Matthew T. Wiley Reports Stock Option Grant
Matthew T. Wiley, Chief Commercial Officer of Mind Medicine (MindMed) Inc., reports the acquisition of stock options for 350,000 common shares.
MindMed's CEO, Robert Barrow, reports the acquisition of 350,000 restricted stock units and shares acquired through the Employee Share Purchase Plan.
Form 4: MindMed's Chief Medical Officer, Dan Karlin, Reports Acquisition of 115,000 Restricted Stock Units
Dan Karlin, Chief Medical Officer of Mind Medicine (MindMed) Inc., reports the acquisition of 115,000 restricted stock units (RSUs) on March 12, 2025.
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., reports the acquisition of 150,000 restricted stock units (RSUs) on March 12, 2025.
Form 4: Mind Medicine (MindMed) Inc. Chief Accounting Officer Receives 50,000 Restricted Stock Units
Carrie Liao, Chief Accounting Officer of Mind Medicine (MindMed) Inc., was granted 50,000 restricted stock units (RSUs) on March 12, 2025, which vest quarterly starting June 1, 2025.
MindMed's CEO, Robert Barrow, sold 19,106 common shares to cover tax obligations related to vested restricted stock units.
Carrie Liao, Chief Accounting Officer of Mind Medicine (MindMed) Inc., sold 2,273 common shares to cover tax obligations related to vested restricted stock units.
MindMed's Chief Medical Officer, Dan Karlin, sold 6,643 common shares on December 26, 2024, to cover withholding tax obligations related to vested restricted stock units.
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., sold 4,519 common shares on December 26, 2024, to satisfy withholding tax obligations related to vested restricted stock units.
Mind Medicine (MindMed) Inc. director David Gryska purchased 2,500 common shares at $7.17 per share on December 5, 2024.
Carrie Liao, Chief Accounting Officer of Mind Medicine (MindMed) Inc., sold 2,352 common shares on September 25, 2024, to cover withholding tax obligations related to vested restricted stock units.
MindMed's CEO, Robert Barrow, sold 19,771 common shares to cover withholding tax obligations related to vested restricted stock units.
Dan Karlin, Chief Medical Officer of Mind Medicine (MindMed) Inc., sold shares to cover withholding tax obligations related to vested restricted stock units.
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., sold 4,430 common shares on September 25, 2024, to satisfy withholding tax obligations related to vested restricted stock units.
Director David W. Gryska increased his holdings in Mind Medicine (MindMed) Inc. by purchasing 3,500 common shares on August 23, 2024.
Miri Halperin Wernli, Executive President of Mind Medicine (MindMed) Inc., exercised stock options and sold shares to cover the exercise price and tax obligations.
MindMed's CEO, Robert Barrow, has recently increased his holdings in the company through open market purchases.